Compare Invesco S&P 500 Momentum ETF (SPMO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Momentum ETF vs BIO-TECHNE Corp — how do they compare? Invesco S&P 500 Momentum ETF trades at $149.97, while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Invesco S&P 500 Momentum ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| SPMO | TECH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $161.66 | $72.12 |
52-Week Low | $107.84 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
